Skip to main content
  • 2017 Robert N. Shaffer Lecture


    Janey Lee Wiggs, MD, PhD, previews her 2017 Robert N. Shaffer Lecture: Glaucoma Genes and New Opportunities for Therapy

    “Precision medicine is defined as an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. The discovery of genes that cause or contribute to glaucoma is an important first step toward the development of precision medicine for glaucoma. Therapeutic decisions that account for personal genetic variation could direct therapy to patients most likely to respond as well as allow for the development of novel gene-based therapies that target disease-causing molecular events. Currently, more than 50 genes have been discovered for various forms of glaucoma, and many of these could be considered as targets for novel therapeutics.”—Dr. Wiggs 

    When: Tuesday Nov. 14, 9:32-9:57 a.m., during Sym47, Development of New Antiglaucoma Medications and Drug Delivery Systems, at AAO 2017. 
    Where: La Nouvelle Orleans AB.

    Development of New Antiglaucoma Medica­tions and Drug Delivery Systems (8:30-10:00 a.m.) is cosponsored by Prevent Blindness.

    This preview was excerpted from EyeNet AAO 2017 News, a tabloid distributed at the Morial Convention Center.